TGTX 114
Alternative Names: TGTX-114; TSHA-114Latest Information Update: 21 May 2024
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Taysha Gene Therapies; University of Texas Southwestern Medical Center
- Class Gene therapies
- Mechanism of Action Fragile X mental retardation protein expression modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Fragile X syndrome
Most Recent Events
- 01 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Fragile X syndrome released by Taysha Gene Therapies
- 31 Dec 2023 Taysha Gene Therapies has one pending patent PCT application for TGTX 114 in-licensed from The Board of Regents of The University of Texas System
- 29 Apr 2020 Taysha Gene Therapies in-licenses TGTX 114 from University of Texas Southwestern Medical Center